Information Provided By:
Fly News Breaks for March 22, 2018
EW
Mar 22, 2018 | 07:11 EDT
Canaccord analyst Jason Mills reiterated his Buy rating on Edwards Lifesciences and reiterated the stock as his top large-cap pick on the heels of the company's update on its low-risk TAVR trial enrollment and upcoming SAPIEN 3 Ultra product launches. In a research note to investors, Mills said Edwards announced enrollment completion within the computed tomography, or CT, subset of the PARTNER 3 trial examining leaflet mobility of both the SAPIEN 3 valve and surgical heart valves in the low-risk patient population and provided an update on the SAPIEN 3 Ultra system launch, expecting CE Mark approval later this year vs. the previously communicated timeline of 1Q18. Mills said his research shows continued fundamental strength in Edwards' TAVR business. He said his $174 price target "could prove conservative."
News For EW From the Last 2 Days
EW
Mar 26, 2024 | 09:30 EDT
OTR Global upgraded its view of Edwards Lifesciences to Positive from Mixed.